Anxo Pharmaceutical Co (ROCO:6677) Cyclically Adjusted Revenue per Share: NT$19.85 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6677 Anxo Pharmaceutical Co Ltd ROCO:6677
56 GF Score
Price NT$16.20
GF Value NT$30.16
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Anxo Pharmaceutical Co Cyclically Adjusted Revenue per Share?

Anxo Pharmaceutical Co ROCO:6677 +0.62% 56 Cyclically Adjusted Revenue per Share is NT$19.85 as of Dec. 2025. GuruFocus rates ROCO:6677 with a GF Score™ of 56/100 and a GF Value™ of NT$30.16 (Possible Value Trap). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Anxo Pharmaceutical Co's adjusted revenue per share data for the fiscal year that ended in Dec. 2025 was NT$15.089. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is NT$19.85 for the trailing ten years ended in Dec. 2025.

During the past 12 months, Anxo Pharmaceutical Co's average Cyclically Adjusted Revenue Growth Rate was -2.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -1.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Anxo Pharmaceutical Co was -1.60% per year. The lowest was -1.60% per year. And the median was -1.60% per year.

As of today (2026-08-04), Anxo Pharmaceutical Co's current stock price is NT$ 16.20. Anxo Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec. 2025 was NT$19.85. Anxo Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is 0.82.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Anxo Pharmaceutical Co was 3.43. The lowest was 0.80. And the median was 1.44.


Anxo Pharmaceutical Co  (ROCO:6677) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Anxo Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=16.20/19.85
=0.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Anxo Pharmaceutical Co was 3.43. The lowest was 0.80. And the median was 1.44.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Anxo Pharmaceutical Co Cyclically Adjusted Revenue per Share Related Terms


Anxo Pharmaceutical Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Anxo Pharmaceutical Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anxo Pharmaceutical Co Cyclically Adjusted Revenue per Share Chart

Anxo Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 20.86 21.22 20.36 19.85

Anxo Pharmaceutical Co Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.22 0.00 20.36 0.00 19.85

ROCO:6677 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Anxo Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anxo Pharmaceutical Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Anxo Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Anxo Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


ROCO:6677
56GF Score
Anxo Pharmaceutical Co Ltd ROCO:6677
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anxo Pharmaceutical Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Anxo Pharmaceutical Co's adjusted Revenue per Share data for the fiscal year that ended in Dec. 2025 was:

Adj_RevenuePerShare=Revenue per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=15.089/324.0540*324.0540
=15.089

Current CPI (Dec. 2025) = 324.0540.

Anxo Pharmaceutical Co Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201612 14.655 241.432 19.670
201712 15.448 246.524 20.306
201812 18.260 251.233 23.553
201912 18.861 256.974 23.784
202012 17.381 260.474 21.624
202112 16.394 278.802 19.055
202212 17.986 296.797 19.638
202312 18.219 306.746 19.247
202412 16.068 315.605 16.498
202512 15.089 324.054 15.089

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of NT$19.85 mean?
Anxo Pharmaceutical Co (ROCO:6677) has a Cyclically Adjusted Revenue per Share of NT$19.85 as of Dec. 2025. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Anxo Pharmaceutical Co and its competitors.
Is Anxo Pharmaceutical Co's Cyclically Adjusted Revenue per Share too high?
Anxo Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is NT$19.85. Overall, Anxo Pharmaceutical Co has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Anxo Pharmaceutical Co's Cyclically Adjusted Revenue per Share compare to ZTS?
Anxo Pharmaceutical Co's Cyclically Adjusted Revenue per Share of NT$19.85 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Anxo Pharmaceutical Co and its competitors. Anxo Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is NT$19.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anxo Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Anxo Pharmaceutical Co (ROCO:6677) is currently considered Possible Value Trap. The stock's GF Value™ is NT$30.16, compared to a current price of NT$16.20 — trading 46.3% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is NT$19.85. Anxo Pharmaceutical Co's overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Anxo Pharmaceutical Co (ROCO:6677), the current Cyclically Adjusted Revenue per Share is NT$19.85 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Anxo Pharmaceutical Co (ROCO:6677) Overvalued in 2026?

Based on GuruFocus' analysis, Anxo Pharmaceutical Co stock appears to be undervalued. The current stock price of NT$16.20 is trading 46.3% below its estimated GF Value™ of NT$30.16. GuruFocus considers Anxo Pharmaceutical Co to be Possible Value Trap.

Key valuation signals for ROCO:6677:

  • Cyclically Adjusted Revenue per Share: NT$19.85
  • GF Value™: NT$30.16 vs. price of NT$16.20 (46.3% below fair value)
  • GF Score™: 56/100 with 4 warning signs

No single metric tells the full story. See the ROCO:6677 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Anxo Pharmaceutical Co Business Description

Address 8th Floor-3, Nanjing East Road, No. 206, Section 2, Taipei City, TWN
Anxo Pharmaceutical Co Ltd is a drug manufacturer. The company is engaged in developing drugs which include prescription medication and consumer healthcare medication. The products of the company include cardiovascular system medication, central nervous system medication, diabetes medication, infectious medicine, and dermatology medication.
56GF Score

Get the complete analysis for ROCO:6677

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$16.20
Price
NT$30.16
GF Value